People: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

85.00CHF
9:35am EDT
Price Change (% chg)

CHF0.35 (+0.41%)
Prev Close
CHF84.65
Open
CHF84.75
Day's High
CHF85.10
Day's Low
CHF83.95
Volume
3,055,350
Avg. Vol
4,945,353
52-wk High
CHF90.60
52-wk Low
CHF67.45

Search Stocks

Epstein, David 

Brief Biography

Mr. David R. Epstein has been Member of the Executive Committee and Division Head, Pharmaceuticals at Novartis AG since February 1, 2010. Prior to his current position, Mr. Epstein served as Head of Novartis Oncology since 2000. He led the Molecular Diagnostics unit of the Company since 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis, Mr. Epstein was an associate in the Strategy Practice of the consulting firm, Booz Allen & Hamilton. Mr. Epstein joined Sandoz, a predecessor company of Novartis, in 1989, and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines. Mr. Epstein graduated with a bachelors degree in pharmacy from Rutgers University College of Pharmacy in 1984, and with a Master of Business Administration in finance and marketing from New York’s Columbia University Graduate School of Business in 1987.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
2,411,450 4,799,460 351,754 7,562,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joerg Reinhardt

1,366,320

Joseph Jimenez

13,228,200

Ulrich Lehner

853,107

Harry Kirsch

--

Peter Kornicker

--

Felix Ehrat

3,584,790
As Of 30 Dec 2012
Search Stocks